Ignite Creation Date:
2024-05-06 @ 8:14 PM
Last Modification Date:
2024-10-26 @ 3:23 PM
Study NCT ID:
NCT06309121
Status:
RECRUITING
Last Update Posted:
2024-04-22
First Post:
2024-02-27
Brief Title:
Effects of the Postbiotic Blend ABB C3 on Adiposity and Glucose Metabolism in Children and Adolescents
Sponsor:
Fundació Sant Joan de Déu
Organization:
Fundació Sant Joan de Déu
Study Overview
Official Title:
Effects of the Postbiotic Blend ABB C3 on Adiposity and Glucose Metabolism in Children and Adolescents
Status:
RECRUITING
Status Verified Date:
2024-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
PostOb
Brief Summary:
This study investigates the effects of a postbiotic combination called ABB C3 on reducing body fat and improving metabolic health in children and teenagers The study consists of a 3-month trial with half participants taking ABB C3 and the other half a placebo monitoring body composition and blood markers Afterward participants can continue with ABB C3 for an additional 3 months The goal is to determine if ABB C3 is a safe and effective way to help young people improve their health by reducing body fat
Detailed Description:
The study focuses on evaluating the effects of a combination of postbiotics called ABB C3 in reducing body fat and improving glucose metabolism The study proposes a randomized double-blind clinical trial with participants aged 8-18 years randomized into the ABB C3 supplement group or a placebo group Over a period of 3 months body composition and relevant blood parameters will be monitored Study Phase Subsequently all participants will be offered to continue with the ABB C3 supplement for an additional 3 months constituting the Follow-up Phase The study protocol includes collecting data on possible adverse events Blood samples and DXA scans will be performed to assess changes in body composition and metabolic health parameters In summary the study aims to determine the efficacy and safety of the ABB C3 postbiotic in helping reduce body fat and improve metabolic profiles in children and adolescents
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None